Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NY-ESO-1 TCR + IL-15 NK
- Development stage
- Phase 2
- Lead developer
- Syena
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
NY-ESO-1 TCR + IL-15 NK is an investigational, off-the-shelf cell therapy composed of cord blood-derived natural killer (NK) cells that are genetically engineered to express an affinity-enhanced T-cell receptor (TCR) targeting the cancer-testis antigen NY‑ESO‑1 and to secrete interleukin 15 (IL‑15). The therapy is designed to combine the innate tumor-targeting ability of NK cells with the antigen specificity of a TCR directed at NY‑ESO‑1, which is highly expressed in several cancers but has limited expression in normal tissues. The addition of IL‑15 supports enhanced survival and proliferation of the engineered cells. This approach aims to improve anti-tumor activity while reducing risks associated with conventional CAR-T or autologous therapies. It is being developed for relapsed or refractory multiple myeloma as well as advanced synovial sarcoma and myxoid/round cell liposarcoma[4][5][6][9].
- Other names
- NY-ESO-1 TCR-NK cell therapyNY-ESO1 TCR-NK cell therapyNY-ESO 1 TCR-NK cell therapy
02
Targets
LAGE-1A/HLA-A*02:01 (L Antigen Family Member 1 peptide/Major Histocompatibility Complex class I complex)
Beyond the preview
Go deeper on NY-ESO-1 TCR + IL-15 NK.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NY-ESO-1 TCR + IL-15 NK.